BioCentury
ARTICLE | Clinical News

Celgene's pomalidomide meets MM endpoint

October 24, 2012 1:20 AM UTC

Celgene Corp. (NASDAQ:CELG) said pomalidomide plus low-dose dexamethasone met the primary endpoint of progression-free survival (PFS) vs. high-dose dexamethasone in the Phase III MM-003 trial to treat...